{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:17:21Z","timestamp":1773148641122,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08HL131867"],"award-info":[{"award-number":["K08HL131867"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"crossref","award":["BIRKET-20A0KB"],"award-info":[{"award-number":["BIRKET-20A0KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DJ072482"],"award-info":[{"award-number":["P30DJ072482"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-024-03029-0","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T15:02:39Z","timestamp":1730732559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivacaftor ameliorates mucus burden, bacterial load, and inflammation in acute but not chronic P. aeruginosa infection in hG551D rats"],"prefix":"10.1186","volume":"25","author":[{"given":"Johnathan D.","family":"Keith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikayla","family":"Murphree-Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen","family":"Bollar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Oden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian H.","family":"Doty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-6596","authenticated-orcid":false,"given":"Susan E.","family":"Birket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"18","key":"3029_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372.","journal-title":"N Engl J Med"},{"issue":"44","key":"3029_CR2","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Supplement","key":"3029_CR3","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S1569-1993(10)60075-6","volume":"9","author":"SM Rowe","year":"2010","unstructured":"Rowe SM, et al. Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo. J Cyst Fibros. 2010;9(Supplement):S20.","journal-title":"J Cyst Fibros"},{"issue":"46","key":"3029_CR4","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor F, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108(46):18843\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3029_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","volume":"11","author":"H Yu","year":"2012","unstructured":"Yu H, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237\u201345.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3029_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Van Goor","year":"2013","unstructured":"Van Goor F, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2013;13(1):29\u201336.","journal-title":"J Cyst Fibros"},{"issue":"17","key":"3029_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","volume":"379","author":"JC Davies","year":"2018","unstructured":"Davies JC, et al. VX-659-tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1599\u2013611.","journal-title":"N Engl J Med"},{"issue":"17","key":"3029_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, et al. VX-445-tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"3029_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","volume":"20","author":"DP Nichols","year":"2021","unstructured":"Nichols DP, et al. PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros. 2021;20(2):205\u201312.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"3029_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2021","unstructured":"Nichols DP, et al. Clinical effectiveness of elexacaftor\/tezacftor\/ivacaftor in people with cystic fibrosis. Am J Respir Crit Care Med. 2021;205(5):529\u201339.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"3029_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","volume":"11","author":"KB Hisert","year":"2023","unstructured":"Hisert KB, et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir Med. 2023;11(10):916\u201331.","journal-title":"Lancet Respir Med"},{"key":"3029_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957","author":"DP Nichols","year":"2023","unstructured":"Nichols DP, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI167957.","journal-title":"J Clin Invest"},{"issue":"2","key":"3029_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","volume":"13","author":"FJ Accurso","year":"2014","unstructured":"Accurso FJ, et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros. 2014;13(2):139\u201347.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3029_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","volume":"16","author":"MC Fidler","year":"2017","unstructured":"Fidler MC, et al. Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor. J Cyst Fibros. 2017;16(1):41\u20134.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3029_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","volume":"190","author":"SM Rowe","year":"2014","unstructured":"Rowe SM, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175\u201384.","journal-title":"Am J Respir Crit Care Med"},{"key":"3029_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122695","author":"SH Donaldson","year":"2018","unstructured":"Donaldson SH, et al. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.122695.","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"3029_CR17","first-page":"S40","volume":"57","author":"ME Gabel","year":"2022","unstructured":"Gabel ME, et al. Overweight and cystic fibrosis: an unexpected challenge. Pediatr Pulmonol. 2022;57(Suppl 1):S40\u20139.","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"3029_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","volume":"75","author":"AC Miller","year":"2022","unstructured":"Miller AC, et al. The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor\u2013tezacaftor\u2013ivacaftor. Clin Infect Dis. 2022;75(7):1115\u201322.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3029_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cid\/ciu944","volume":"60","author":"SL Heltshe","year":"2015","unstructured":"Heltshe SL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60(5):703\u201312.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3029_CR20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert KB, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. 2017;195(12):1617\u201328.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3029_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","volume":"202","author":"SE Birket","year":"2020","unstructured":"Birket SE, et al. Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR. Am J Respir Crit Care Med. 2020;202(9):1271\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3029_CR22","doi-asserted-by":"publisher","first-page":"L1093","DOI":"10.1152\/ajplung.00082.2021","volume":"320","author":"M Green","year":"2021","unstructured":"Green M, et al. Ivacaftor partially corrects airway inflammation in a humanized G551D rat. Am J Physiol Lung Cell Mol Physiol. 2021;320(6):L1093\u2013100.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"3029_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.97199","volume":"3","author":"SE Birket","year":"2018","unstructured":"Birket SE, et al. Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight. 2018;3(1): e97199.","journal-title":"JCI Insight"},{"issue":"3","key":"3029_CR24","doi-asserted-by":"publisher","first-page":"2101032","DOI":"10.1183\/13993003.01032-2021","volume":"60","author":"AG Henderson","year":"2022","unstructured":"Henderson AG, et al. Static mucus impairs bacterial clearance and allows chronic infection with Pseudomonas aeruginosa in the cystic fibrosis rat. Eur Respir J. 2022;60(3):2101032.","journal-title":"Eur Respir J"},{"key":"3029_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.884166","volume":"13","author":"JD Keith","year":"2022","unstructured":"Keith JD, et al. Muc5b contributes to mucus abnormality in rat models of cystic fibrosis. Front Physiol. 2022;13: 884166.","journal-title":"Front Physiol"},{"issue":"10","key":"3029_CR26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/rccm.201708-1616OC","volume":"197","author":"BH Rosen","year":"2018","unstructured":"Rosen BH, et al. Infection is not required for mucoinflammatory lung disease in CFTR-knockout ferrets. Am J Respir Crit Care Med. 2018;197(10):1308\u201318.","journal-title":"Am J Respir Crit Care Med"},{"issue":"485","key":"3029_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7531","volume":"11","author":"X Sun","year":"2019","unstructured":"Sun X, et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med. 2019;11(485): eaau7531.","journal-title":"Sci Transl Med"},{"issue":"3","key":"3029_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091253","volume":"9","author":"KL Tuggle","year":"2014","unstructured":"Tuggle KL, et al. Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats. PLoS ONE. 2014;9(3): e91253.","journal-title":"PLoS ONE"},{"issue":"2","key":"3029_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jcf.2013.08.007","volume":"13","author":"TJ Cory","year":"2014","unstructured":"Cory TJ, et al. Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros. 2014;13(2):164\u201371.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3029_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054473","volume":"8","author":"L Liu","year":"2013","unstructured":"Liu L, et al. Method for quantitative study of airway functional microanatomy using micro-optical coherence tomography. PLoS ONE. 2013;8(1): e54473.","journal-title":"PLoS ONE"},{"issue":"4","key":"3029_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.201404-0670OC","volume":"190","author":"SE Birket","year":"2014","unstructured":"Birket SE, et al. A functional anatomic defect of the cystic fibrosis airway. Am J Respir Crit Care Med. 2014;190(4):421\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3029_CR32","doi-asserted-by":"publisher","first-page":"2100185","DOI":"10.1183\/13993003.00185-2021","volume":"59","author":"CB Morrison","year":"2022","unstructured":"Morrison CB, et al. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration. Eur Respir J. 2022;59(2):2100185.","journal-title":"Eur Respir J"},{"issue":"5","key":"3029_CR33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jcf.2024.05.006","volume":"23","author":"B Capraz Yavuz","year":"2024","unstructured":"Capraz Yavuz B, et al. Impact of interruption of CFTR modulator therapies. J Cyst Fibros. 2024;23(5):947\u20139.","journal-title":"J Cyst Fibros"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-03029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-03029-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-03029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T08:07:35Z","timestamp":1730880455000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-03029-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3029"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-03029-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures involving animals were approved by the IACUC at UAB (IACUC-20532, IACUC-21963, and IACUC-22206).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"397"}}